Stock Market Reviews

RGEN (Repligen Corporation) News

Get the latest news, insights, and market updates on RGEN (Repligen Corporation). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Is It Too Late To Consider Buying Repligen Corporation (NASDAQ:RGEN)?
  Repligen Corporation ( NASDAQ:RGEN ), is not the largest company out there, but it saw a double-digit share price rise...
  Jan 19, 2026 - $RGEN
• 3 High-Flying Stocks That Fall Short
  Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
  Jan 19, 2026 - $RGEN
• Why Repligen (RGEN) Shares Are Sliding Today
  Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 3.9% in the afternoon session after the company presented at the JPMorgan Healthcare Conference and shared its sales guidance for 2025.
  Jan 14, 2026 - $RGEN
• Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
  WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. “On
  Jan 6, 2026 - $RGEN
• 1 Cash-Heavy Stock to Target This Week and 2 Facing Challenges
  A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
  Jan 6, 2026 - $RGEN
• 3 Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025
  As the United States market kicks off a holiday-shortened week, major stock indexes like the S&P 500, Nasdaq, and Dow Jones Industrial Average have shown gains, buoyed by advances in tech shares and record highs in gold and silver. Amidst this positive momentum, investors are keenly focused on identifying stocks that may be trading below their intrinsic value, presenting potential opportunities for those looking to capitalize on undervalued assets.
  Dec 22, 2025 - $RGEN
• Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
  WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live webcast of the conference presentations will be accessible throug
  Dec 18, 2025 - $RGEN
• Here’s Why Sands Capital Global Growth Fund Decided to Sell Repligen Corporation (RGEN)
  Sands Capital, an investment management company, released its “Sands Capital Global Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global Growth adopts a flexible approach to identify the most promising growth companies worldwide. Global equities surged in the quarter, although leadership remains concentrated. In this environment, the strategy […]
  Dec 17, 2025 - $RGEN
• Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
  WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company’s growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™ DuloC
  Dec 16, 2025 - $RGEN
• The five-year earnings decline is not helping Repligen's (NASDAQ:RGEN share price, as stock falls another 3.3% in past week
  It is doubtless a positive to see that the Repligen Corporation ( NASDAQ:RGEN ) share price has gained some 35% in the...
  Dec 9, 2025 - $RGEN